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Abstract
Out-of-pocket payments might threaten the vertical equity of financing and generate unmet
medical needs. The main objective was to assess the vertical equity of outpatient out-of-
pocket payments for lymphedema patients in France. Twenty-seven centres, among which
11 secondary care hospitals and 16 primary care practices participated in this prospective
national multicenter study. We measured the lymphedema-specific outpatient out-of-pocket
payments over 6 months. The vertical equity of out-of-pocket payments was examined
using concentration curves, the Gini coefficient for income, the Kakwani index, and the Rey-
nolds-Smolensky index. We included 231 lymphedema patients aged 7 years or more, living
in metropolitan France, and being able to use Internet and email. After voluntary health
insurance reimbursement, the mean out-of-pocket payment was equal to 101.4 Euros
per month, mainly due to transport (32%) and medical devices (26%). Concentration
curves indicated regressivity of out-of-pocket payments. Total out-of-pocket payments rep-
resented 10.1% of the income by consumption unit for the poorest quintile and 3.5% for the
wealthiest (p<0.05). The Kakwani index for out-of-pocket payments was equal to -0.18.
Regarding outpatient health care, French lymphedema patients face significant and
regressive out-of-pocket payments, associated with an increased risk of unmet medical
needs. Such results shed light on significant socioeconomic inequalities and bring into ques-
tion the current financing arrangements of outpatient health care in France.
Trial registration: ClinicalTrials.gov ID: NCT02988479
Introduction
Out-of-pocket payments (OOPP) are defined as the involvement of the patient in the payment
of health care services [1, 2]. They have been increasingly implemented to enhance the
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efficiency of health systems. OOPP might decrease moral hazard, that is to say the theoretical
overconsumption of health care due to health insurance [2, 3]. OOPP can take the form of
co-insurance (a proportion of the service cost), co-payment (flat-rate fees per service), and
deductibles (payment of the actual cost up to a given amount before the insurance kicks
in) [2].
Nonetheless, OOPP might threaten the efficiency and equity principles of health care sys-
tems. First, high OOPP are associated with unmet medical needs [4]. Second, they might create
inequities. Following the principle of vertical equity in the financing of health care, individuals
with unequal ability to pay should pay unequally for a given level of health [5, 6].
In France, the publicly-funded mandatory health insurance (MHI) scheme (Assurance
Maladie) covers 79% of the total health care expenditure [7]. The MHI coverage is more
important for inpatient care (91%) than for outpatient care (63%). In the ambulatory care sec-
tor, extra-billing is allowed for out-patient specialist medical visits, and some prescription
medical devices have a free selling price above the statutory tariff. Other medical devices are
either prescribed but not listed or over-the-counter and are therefore not reimbursed at all by
the MHI scheme. A flat-rate copayment is applied per service (0.5 Euro for non-physician ser-
vices, drugs and medical devices, 1 Euro for physician visits, medical imaging and laboratory
tests, and 2 Euros for transport) up to a 50 Euros annual ceiling to all services. This ceiling
does not include extra-billing or selling prices above the statutory tariff. Almost 90% of the
population is covered by voluntary health insurance (VHI) that covers 14% of the health care
expenditure and plays a complementary role. VHI schemes usually reimburse the MHI co-
insurance fee up to 100% of the statutory tariff, and some contracts cover extra-billing. VHI
are not allowed to cover the flat-rate co-payment. The poorest individuals are eligible to one of
the publicly-funded complementary insurance schemes: couverture maladie universelle com-
plementaire (CMUc) or aide a la complementaire sante (ACS). Under these schemes, patients
have full coverage without co-insurance, and extra-billing is forbidden. Moreover, patients
covered by the disease-based exemption scheme (affection de longue duree; ALD) are
exempted from co-payments and co-insurance for health care related to a list of chronic
conditions.
OOPP spending in France amounts to 8% of the health care expenditures in 2015 [7]. How-
ever, OOPP are unevenly distributed across services and the population. They are concen-
trated on outpatient health care services and on high-risk, high-spending individuals [8, 9]. In
a 2005 study, the mean annual OOPP for outpatient care amounted to 529€ (SD = 1984€) after
MHI reimbursement and to 200€ (SD 1174€) after VHI reimbursement [10]. Measuring post-
VHI OOPP is particularly challenging in France due to difficult access to VHI data. In addi-
tion, the rare published studies do not account for patients’ health status or for unmet medical
needs. Therefore, from a policy perspective, understanding the relationship among OOPP,
income, health status and unmet medical needs is of utmost importance.
Lymphedema is a chronic condition associated with pain and swelling that poses a signifi-
cant burden on patients [11]. Despite its prevalence reaching 4 per 1000 population [12], the
population implications of lymphedema are not well studied [13]. According to current clini-
cal guidelines, patients with lymphedema are primarily managed on an outpatient basis, with
compression devices playing a key role on a lifelong basis. Though the evidence is scarce, sev-
eral randomized controlled trials have demonstrated the efficacy of compression therapy on
various outcomes (i.e. limb volume, symptoms severity, and functional status), both at the
acute and maintenance phases[14–18]. Lymphedema patients in France are, hence, likely to
experience high OOPP.
The aim of this study was to assess the inequalities in OOPP in patients living with lymph-
edema in France.
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Materials and methods
Study design
We conducted a prospective and multicenter cohort study in France between 2014 and 2015.
The main inclusion criteria were having a lymphedema, being aged 7 years or more, living
in metropolitan France, and being able to use Internet and email. Lymphedema patients were
included in a convenience sample of 27 centres, among which 11 were public or private hospi-
tals and 16 were individual physicians or physiotherapists working in a private practice. Each
centre included all the consecutive patients who met the inclusion criteria during the study
period. Because we anticipated a high drop-out rate due to the data collection burden, we ran a
1-month pre-inclusion phase. Only patients who agreed to participate at the end of the pre-
inclusion phase were included in the study. All patients (or their legal representative) signed a
written informed consent prior to inclusion. The study was approved by the French institu-
tional review board (CPP Sud Mediterranee V; approval number 2014-A00716-41).
Data collection
Data collection was standardized using a paper questionnaire filled in by health care profes-
sionals and an electronic questionnaire filled in by patients on a dedicated and secured Inter-
net website. The professionals provided demographic and clinical data, and patients reported
socio-economic and clinical data, health care services utilization, cost and reimbursement, and
health-related quality of life measures. Health care service utilization was collected weekly. To
ensure high-quality data, we accompanied patients and professionals with initial training, real-
time data quality monitoring and active email and telephone communication.
We collected the following socio-economic data: employment status and category [19],
monthly net post-tax household income (using an 11-category scale), VHI and special schemes
entitlements (CMUc, ACS and ALD). Questions were asked about the travel distance to seek
lymphedema care and subjective unmet medical needs due to travel distance or cost. A patient
had a subjective unmet medical need when she declared having forgone in the previous year at
least one of the lymphedema care recommended by the current French clinical guidelines [20]:
medical visits, compression medical devices or physiotherapy. The monthly income by con-
sumption unit (CU) was calculated according to the modified equivalence scale of the Organi-
zation for Economic Co-operation and Development (OECD). Consumption units are a
standardized measure of the size of a household determined as follows: the first adult has a
weight of 1.0, each subsequent adult has a weight of 0.7, and each person under 18 has a weight
of 0.5. During the six-month follow-up, service utilization, cost and reimbursement (by MHI
and by VHI, if any) were prospectively collected for the following outpatient health care ser-
vices: physician visits, non-physician services, imaging and laboratory tests, drugs, prescription
and over-the-counter medical devices (bandaging, multi-layer inelastic bandaging, pneumatic
compression, compression garments, sticking-plaster, wound dressing), and transportation.
Inpatient care was collected but not analyzed, because (i) lymphedema patients are primarily
managed in the outpatient setting, and (ii) inpatient care may have generated very high
amounts of OOPP for very few patients. Non-medical cost was considered as follows: house-
keeping or childcare, cosmetics, clothes, shoes, and thermal therapies. Housekeeping and
childcare were considered to account for the impact on family life. We included cosmetics,
clothes and shoes because lymphedema often results in significant changes in skin colour and
in the circumferences of limbs [11]. Finally, lymphedema patients often rely to thermal thera-
pies in France [20]. Two types of OOPP were estimated: after MHI reimbursement and after
MHI and VHI reimbursement.
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Two quality of life-related measures were assessed: utility values derived from the EQ5D-3L
with the French index values[21]. In the absence of French index values, capability scores were
obtained from the ICECAP-A [22] using the UK index values[23].
Missing or inconsistent data
Missing or inconsistent cost data for services with a statutory tariff were corrected using the
adequate tariff, assuming no extra-billing. Regarding services without a statutory tariff (i.e.,
medical devices, transport and non-medical services), costs and reimbursements were checked
directly with the patients by telephone.
Sample size and statistical analyses
The sample size was calculated to estimate the annual OOPP with a given precision. We
hypothesized a mean OOPP equal to 200€ and a standard deviation equal to 1150€ [10]. To
have a 95% confidence interval with a total width equal to 300, 230 patients were required.
Descriptive analyses were performed using frequencies and proportions for qualitative vari-
ables and mean, median, standard deviation and range for quantitative variables. Comparative
univariate analyses were performed using the Student’s or Wilcoxon test for quantitative vari-
ables and the Chi2 or Fisher test for qualitative variables.
To analyze the income-group differences in OOPP, we split the sample into 5 income per
CU groups, each group representing one-fifth of the whole sample. Hence, the first income
quintile refers to the poorest 20% and the fifth to the wealthiest 20%.
The vertical equity of OOPP was examined by describing the relationship between the abil-
ity to pay (measured by income per CU) and the amount of OOPP. We followed a standard
strategy combining disaggregated and aggregated measures [24, 25]. Disaggregated evidence is
presented graphically by comparing the concentration curve of income (Lorenz curve) and the
concentration curve of OOPP. The Lorenz curve plots the cumulative share of the sample
(from the poorest to the wealthiest) against the cumulative share of the total income they
receive. The OOPP concentration curve plots the cumulative share of the sample (similarly to
the Lorenz curve) against the cumulative share of OOPP. If the OOPP is strictly proportional
(i.e., patients pay the same proportion of their income), then the Lorenz and OOPP concentra-
tion curves will overlap. When the poorest patients pay a higher proportion of their income
(regressive payment system), then the OOPP concentration curve lies above the Lorenz curve.
Aggregated measures are the Gini coefficient for income, the Kakwani index for OOPP and
the Reynolds-Smolensky index. The Kakwani index K is calculated by subtracting the Gini
coefficient G for income from the concentration index for OOPP, and it quantifies the extent
to which OOPP depart from proportionality. The Kakwani index is negative when there are
vertical inequities favouring the rich (regressive payment system) and positive when there are
vertical inequities favouring the poor (progressive payment system). The Reynolds-Smolensky
index measures the overall redistributive effect of OOPP on income and includes some hori-
zontal inequities [26].
All analyses were performed using SAS software, version 9.2.
Results
A total of 305 patients were screened, 301 were eligible and participated in the pre-inclusion
phase, 70 refused to participate after the pre-inclusion phase, and 231 were recruited (Fig 1).
Finally, 203 patients were included in the analysis. The mean follow-up duration was 5.57
months (SD = 1.05), patients were aged 55 years on average (SD = 14.2), 6 were aged less than
18 years, and 85.7% were female (Table 1). The mean household income was 2,012 Euros per
Out-of-pocket payments for lymphedema patients in France
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consumption unit. Regarding complementary health insurance, 97.6% of patients were cov-
ered by a VHI and 2% were entitled to a social complementary health insurance scheme.
The outpatient health care expenditure related to lymphedema amounted to 253.1 Euros
(SD = 243.1) per patient per month (Table 2). Non-physician services, transport and medical
devices accounted for 30%, 23% and 19% of the total expenditure, respectively. After VHI
reimbursement, the mean OOPP was equal to 101.4 Euros (SD = 100) per month, mainly due
to transport (32%) and medical devices (26%). Indeed, the mean OOPP for medical devices
and transport amounted to 32.9 Euros (SD = 68.7) and 26.2 Euros (SD = 35.9) per month,
respectively. In terms of financial burden, the mean OOPP amounted to 1,212 Euros per year
or 5.4% of the annual income on average.
Fig 1. Flowchart.
https://doi.org/10.1371/journal.pone.0216386.g001
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Table 3 shows the income, health status, health care expenditure, OOPP, and subjective
unmet medical needs for each income quintile of the sample. The poorest patients had a
poorer health status, as measured by the EQ5D-3L (0.62 for quintile 1 vs. 0.75 for quintile 5,
p<0.05) and by the ICECAP-A (0.79 for quintile 1 vs. 0.90 for quintile 5, p<0.05). Although
the differences are not statistically significant, there is a tendency toward lower total health
Table 1. Sample characteristics.
Characteristics Mean (SD) / N (%)
Follow-up (months) 5.6 (1.1)
Women (%) 174 (85.7%)
Age (years) 55 (14.2)
BMI (kg/m2) 27 (6.6)
Lymphedema type:
• Primary 69 (34%)
• Secondary 134 (66%)
Lymphedema location:
• Upper Limb 95 (46.8%)
• Lower Limb 105 (51.7%)
• Upper and lower limbs 3 (1.5%)
Lymphedema severity:
• Stage 1 21 (10.4%)
• Stage 2 163 (80.3%)
• Stage 3 19 (9.3%)
Lymphedema duration:
• from 6 months to 5 years 105 (51.7%)
• from 5 years to 10 years 28 (13.8%)
• above 10 years 70 (34.5%)
Comorbidities:
• None 132 (65%)
• Cancer 44 (21.7%)
• Others 27 (13.3%)
Wound infection 40 (19.7%)
Hospitalization because of wound infection 30 (14.8%)
Household size (CU) 1.7 (0.7)
Household monthly income (€) 3,320 (1,861)
Monthly income per CU (€) 2,012 (1,191)
Socio-professional category:
• Active 123 (60.6%)
• Inactive 18 (8.9%)
• Retired 62 (30.5%)
Voluntary Health Insurance (VHI) (%) 198 (97.5%)
VHI upgrade for lymphedema care 47 (23.2%)
VHI annual premium (€) 1,293 (788)
Chronic illness exemption scheme (ALD) 144 (70.9%)
Social complementary health insurance (CMUc or ACS) 4 (2%)
SD: standard deviation; BMI: body mass index; CU: consumption unit; VHI: voluntary health insurance; ALD:
affection de longue duree; CMUc: couverture maladie universelle complementaire; ACS: aide a la complementaire
sante.
https://doi.org/10.1371/journal.pone.0216386.t001
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care expenditure (225.3€ for quintile 1 vs. 251.4€ for quintile 5, p>0.05), lower VHI premiums
(1,110€ for quintile 1 vs. 1,452€ for quintile 5, p>0.05), and lower OOPP (82.4€ for quintile 1
vs. 126.7€ for quintile 5, p>0.05). Total OOPP represented a higher share of the income by
consumption unit (10.1% for quintile 1 vs. 3.5% for quintile 5, p<0.05); the same held true for
OOPP due to medical devices (3.1% for quintile 1 vs. 1.1% for quintile 5, p<0.05). In total, 63
patients (31%) declared subjective unmet medical needs related to lymphedema, among which
79% were because of cost and 21% because of distance to the provider. The poorest patients
declared such unmet needs more often (54% for quintile 1 vs. 17% for quintile 5, p<0.05).
Fig 2 shows the concentration curve of income per CU (Lorenz curve) and the concentra-
tion curve of total post-VHI OOPP. The concentration curve for OOPP is above the Lorenz
curve and close to the 45-degree line, indicating regressivity. The Gini coefficient for income
was equal to 0.29, and the concentration index for OOPP was equal to 0.11. Hence, the
Table 2. Lymphedema-related outpatient health care expenditures and OOPP per month.
Resource Expenditures (€) Out-of-pocket payments (€)
After MHI After VHI
Outpatient physician visits 9.9 (19.9) 1.8 (7.1) 1.1 (5.1)
Outpatient non-physician services 75.6 (77.6) 9.2 (22.9) 4.2 (18.4)
Outpatient laboratory and imaging tests 5.7 (22.3) 0.8 (5.3) 0.1 (0.6)
Pharmaceuticals 5.5 (25.4) 1.1 (4.1) 0.9 (3.7)
Medical devices 48.8 (49.7) 36.2 (41.6) 26.2 (35.9)
Transport 57.6 (112.8) 33.1 (69.1) 32.9 (68.7)
Thermal therapy 22.7 (67.7) 11.1 (36.6) 8.6 (29.7)
Others 27.5 (81.4) 27.3 (81.5) 27.3 (81.5)
TOTAL 253.1 (243.1) 120.5 (132.1) 101.4 (123.1)
Data presented are mean (standard deviation). MHI: mandatory health insurance; VHI: voluntary health insurance.
https://doi.org/10.1371/journal.pone.0216386.t002
Table 3. Distributional analysis of health status, expenditures, OOPP and unmet medical needs by income quintiles.
Q1 Q2 Q3 Q4 Q5 p-value
Income by CU (€) 817.5
(243.3)
1,354.6
(170.3)
1,800.2
(149.1)
2,480.5
(70.2)
3,601.5
(1,516.3)
�
Outpatient health care expenditures (€) 225.3
(168.1)
240.9
(198.1)
242.9
(217.4)
306.2
(384.9)
251.4
(190.6)
Post-VHI total OOPP (€) 82.4
(76.6)
85.3
(95.7)
108.3
(154.4)
103.9
(149.3)
126.7
(121.8)
Post-VHI OOPP due to transport (€) 29.6
(47.3)
28.9
(52.6)
53.3
(121.6)
23.3
(39.4)
28.9
(45.4)
Post-VHI OOPP due to medical devices (€) 25.5
(27.5)
21.8
(28.0)
16.8
(16.9)
27.9
(30.9)
39.1
(58.9)
�
Total OOPP / income ratio (%) 10.1 6.3 6.0 4.2 3.5 �
Transport OOPP / Income ratio (%) 3.6 2.1 3.0 0.9 0.8
Medical devices OOPP / Income ratio (%) 3.1 1.6 0.9 1.1 1.1 �
Subjective unmet medical needs (n, %) 22 (54%) 13 (33%) 15 (37%) 6 (15%) 7 (17%) �
EQ5D-3L 0.6
(0.2)
0.7
(0.3)
0.8
(0.2)
0.8
(0.2)
0.8
(0.2)
�
ICECAP-A 0.8
(0.2)
0.7
(0.2)
0.8
(0.2)
0.8
(0.2)
0.9
(0.1)
�
� P-value < 0.05
https://doi.org/10.1371/journal.pone.0216386.t003
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Kakwani index for total OOPP was equal to -0.18, denoting the regressive effect of OOPP in
lymphedema patients. For instance, the poorest 20% of the sample receives less than 8% of the
total income and pays 16% of the total OOPP. The Reynolds-Smolensky index was equal to
-0.01.
Discussion
In this study, French patients with lymphedema experience significant post-VHI OOPP
regarding outpatient health care. Indeed, even though we focused on a single condition, the
annual OOPP due to outpatient lymphedema care (101 € per month or 1,212 € per year) is 6
times higher than the average annual OOPP for outpatient care of the general population in
France (200€ per year) [10]. Although the rate of OOPP as a percentage of total expenditures
on health is low in France compared to other OECD countries [7], the results confirm that
OOPP are high for patients with chronic diseases and are concentrated on few health care ser-
vices, including prescription medical devices. This financial burden posed by lymphedema-
related OOPP amounted to 5.4% of the annual income on average, which is more than five
times higher than the average financial burden of the general French population, i.e. 1%[10].
This is all the more true that our study focused on a single condition.
Approximately 60% of these OOPP are due to medical devices and to transport, although
they represent less than 50% of the total expenditure. This points to the central role of medical
devices in the current clinical guidelines [20] and to the paucity of reference centres in France.
Additionally, the high share of OOPP due to medical devices raises the issue of the current
pricing policy of prescription medical devices that allows for free selling prices above the exist-
ing statutory tariffs. Almost one-third of the patients declared having forgone lymphedema-
related health care because of cost or distance to seek care. This rate of subjective unmet medi-
cal needs is higher than that usually measured on the general population. Indeed, in 2012, 26%
Fig 2. Concentration curve for total out-of-pocket payments.
https://doi.org/10.1371/journal.pone.0216386.g002
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of the general French population said they had forgone medical care, but 75% of the declared
unmet medical needs were related to dental care and vision care [27]. In the same study, 3% of
the general population had forgone medical care because of distance, versus 12% in our
lymphedema sample. On unmet medical needs, the OECD data focus on forgone medical or
dental examination, and hence, the French average is lower (4.5%) [7]. Unmet medical needs
are usually associated with poorer health status and lower health care utilization [4]. This
holds true in our study and is consistent with published evidence from France [28].
The burden of OOPP fell unequally on different income groups, with patients from the
poorest quintile paying an approximately three times larger share of their income than patients
from the wealthiest quintile. This suggests that the principle of vertical equity in financing is
violated [7]. The negative Kakwani index for total OOPP (-0.18) confirms the regressive role
of OOPP in the income of lymphedema patients. This result is consistent with studies from
other high-income countries suggesting a regressive effect of expenditures on medical devices
on income in Austria [29] and in Hungary [30]. More generally, OOPP have been shown to
increase inequalities in access to healthcare in Western and Eastern European countries [31].
The regressive effect of post-VHI OOPP in our lymphedema sample is a little lower than the
regressive effect of post-MHI OOPP in the general population (-0.21; [32]). Both are for outpa-
tient care only, but the population is significantly different in terms of age, gender and comor-
bidities. Hence, a direct comparison is challenging. In theory, such inequalities could be
explained by the effect of different health statuses or preferences. Here, the poorest patients
have lower total health care expenditures, poorer health status, and a higher rate of subjective
unmet medical needs. Although they are in poorer health, the less-affluent patients have lower
health care expenditures. This finding is in line with the published evidence from other coun-
tries with generous welfare arrangements and might be explained by a range of factors includ-
ing cultural capital, psychosocial stress, material resources, and geographical segregation [33].
Strengths and limitations
This study suffers from some limitations that should be acknowledged. First, we had to exclude
28 patients for whom data on out-of-pocket payment was missing. However, we did so to
improve the data quality, and there is no argument for a systematic bias. Second, we improved
the representativeness of the sample by including a wide range of public and private centres
throughout the country, and by including all consecutive patients who met the inclusion crite-
ria in each centre. However we were not able to check the representativeness because of lack-
ing data on the characteristics of the lymphedema centres and patients in France. In addition,
because we did not include patients who were unable to use the Internet and email, the oldest
and most disabled patients are likely to be underrepresented in our study sample. Again, we
do not believe this might challenge the main findings. Finally, our analysis is focused on ambu-
latory care costs and it might be argued that inpatient care could generate very high out-of-
pocket costs. However, we did so because inpatient admissions would have generated high
costs but very low out-of-pocket costs. Indeed, out-of-pocket costs are concentrated on ambu-
latory care services in France for several reasons [8, 9]: inpatient care is predominantly covered
by the mandatory social insurance (91% on average, vs. 63% for ambulatory services), hospital
medical devices are not billed to patients, transportation from and to hospitals are covered by
the mandatory social insurance, and there is no extra-billing.
Nevertheless, this is one of the only OOPP studies in France accounting for a wide array of
data. Indeed, we were able to prospectively collect socio-economic and clinical data as well as
unmet medical needs and reimbursements by VHI that are not available in standard retrospec-
tive analyses. The national, multicenter and primarily outpatient-based pre-screening and
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screening certainly made the sample representative of the whole lymphedema population. As
an example, the Gini coefficient for income in our sample (0.286) is very close to that of the
French general population measured in 2013 (0.294; [34]. Finally, the data quality check pro-
cess allowed us to control the impact of missing and inaccurate data.
Policy implications
We show that the vertical equity principle is violated regarding the financing of outpatient
lymphedema health care in France. Although cost-sharing has been implemented in most
European countries, its ability to reduce the utilization of unnecessary health care remains
unclear [2, 35]. According to the most widely accepted prevalence data[11], the total number
of patients living with a lymphedema in France is equal to 268,000. Based on this figure and on
our results, taking over the transportation OOPP (32.9 Euros per patient per month) would
cost 105.8 Million Euros per year to the system. Similarly, eliminating the medical devices
OOPP (26.2 Euros per patient per month) would cost 84.3 Million Euros per year. However,
improving the vertical inequity does not imply eliminating OOPP. In France, various income-
or disease-based mechanisms should control OOPP. However, they are not effective in pro-
tecting the poorest households from high levels of OOPP. Other budget-neutral or not options
should be considered, such as adding a ceiling on OOPP [36] to the existing financing mecha-
nisms, with or without removing the disease-based ALD exemption scheme [37]. Another
option could be to implement a single co-payment for outpatient care with an annual ceiling,
which may or may not be modified according to income alone [38] or to income and house-
hold composition [39].
As regards prescription medical devices specifically, OOPP are frequently explained by the
difference between the statutory service and the selling price. Policy makers should therefore
reconsider the possibility of charging a free selling price for medical devices. Likewise, the
large amount of OOPP due to transport stresses the issue of geographical access to reference
centres across the country. Possible levers for action include an improved distribution of refer-
ence centres across the territory and telehealth.
More generally, our results contribute to the debate about the consequences of cost-sharing
in health care. Cost-sharing mechanisms have constantly been associated with reduced health
care utilization and expenditures since the seminal RAND experiment [40]. But the conse-
quences on health status are controversial: greater cost sharing is associated with reduced use
of unnecessary care but also with reduction in utilization of high-value care such as long-term
medications and preventive services [41, 42]. Our study suggests that patients facing out-of-
pocket costs regarding ambulatory care for chronic oedema declare unmedical medical needs
more often than the general population (31% vs. 26%, though figures are not directly compara-
ble). Furthermore, the poorest patients declare more unmet medical needs, have lower total
health care expenditures, have lower level of quality of life, and dedicated a higher share of
their income to out-of-pocket costs. However, investigating whether these patients forgo nec-
essary or unnecessary services was beyond the scope of our observational study and should be
investigated using a natural experiment design.
Conclusion
This work shows that regarding outpatient health care, French lymphedema patients face sig-
nificant and regressive OOPP, associated with an increased risk of unmet medical needs. Such
results shed light on significant socioeconomic inequalities and bring into question the current
financing arrangements of outpatient health care in France.
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